Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Body Weight

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,388 result(s) found for: Body Weight. Displaying page 1 of 170.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-003395-22 Sponsor Protocol Number: W3600586 Start Date*: 2008-09-04
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition
    Medical condition: Weight Loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006986-10 Sponsor Protocol Number: W3680604 Start Date*: 2009-02-04
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004797-79 Sponsor Protocol Number: W2660371 Start Date*: 2007-09-28
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000677-31 Sponsor Protocol Number: STH15216 Start Date*: 2011-09-16
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Testosterone Replacement in Young Male cancer Survivors
    Medical condition: Borderline low levels of testosterone in male cancer survivors who have previously had leukaemia, lymphoma or testicular cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10047900 Weight loss LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004275-70 Sponsor Protocol Number: GPD-01-01 Start Date*: 2016-01-08
    Sponsor Name:Gene PreDiT SA
    Full Title: Influence of single nucleotide polymorphisms of carboxypeptidase D (CPD) gene on body weight and fat mass reduction by perindopril in obese subjects: A phase II, multicenter, double-blind study.
    Medical condition: Body weight and fat mass reduction by perindopril in obese subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002145-15 Sponsor Protocol Number: NOK0023 Start Date*: 2023-10-31
    Sponsor Name:Nederlandse Obesitas Kliniek
    Full Title: Applying Mysimba in patients with weight regain after bariatric surgery
    Medical condition: Weight regain post bariatric surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004866-15 Sponsor Protocol Number: EMI111963 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Longitudinal MRI Study of Changes in Regional Body Composition During Orlistat (60mg)-Assisted Dieting
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000790-94 Sponsor Protocol Number: NN9536-4999 Start Date*: 2022-11-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity.
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) NO (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004998-13 Sponsor Protocol Number: LP0160-1329 Start Date*: 2020-06-02
    Sponsor Name:LEO Pharma A/S
    Full Title: Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight
    Medical condition: moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003569-91 Sponsor Protocol Number: NL62896 Start Date*: 2017-12-08
    Sponsor Name:Hagaziekenhuis
    Full Title: The effect of body weight on trough concentrations of DOACs in patients.
    Medical condition: No medical condition will be investigated. This study will only investigate the effect of body weight on through concentrations of direct oral anticoagulants (DOACs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002364-29 Sponsor Protocol Number: 015 Start Date*: 2005-09-02
    Sponsor Name:
    Full Title: A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000956-32 Sponsor Protocol Number: 20022012 Start Date*: 2012-06-28
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients
    Medical condition: Morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001540-38 Sponsor Protocol Number: NN9536-4153 Start Date*: 2015-08-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, mul...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004366-14 Sponsor Protocol Number: MK-0364 012 Start Date*: 2006-11-13
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: Full title of the trial A Study to Assess the Efficacy and Tolerability of MK-0364 in Maintaining Weight Loss Induced by Diet in Obese Patients Followed by a 1-Year Extension
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002816-19 Sponsor Protocol Number: Frax001 Start Date*: 2012-10-25
    Sponsor Name:Rijnstate Hospital
    Full Title: Prospective, pharmacokinetic study for determination of the relationship between lean body weight and anti-Xa activity 4 hours after subcutaneous injection of 5700 IU nadroparin in morbidly obese p...
    Medical condition: patients; perioperative in bariatric surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003426-24 Sponsor Protocol Number: CTU079G Start Date*: 2013-02-13
    Sponsor Name:Riemser Pharma GmbH
    Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m²
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002235-60 Sponsor Protocol Number: NN9536-7545 Start Date*: 2023-02-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000220-19 Sponsor Protocol Number: 2.2 Start Date*: 2020-09-24
    Sponsor Name:Verein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung der Krankenanstalt Rudolfstiftung
    Full Title: Comparing effects of weight loss by Liraglutide 3.0 mg with conventional liver fasting in non-alcoholic fatty liver disease before bariatric surgery
    Medical condition: Obesity and NAFLD can increase the risk and complexity of bariatric surgery up to 20%. Reducing the weight and liver size before bariatric surgery improves the operation area and reduces complicati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005435-75 Sponsor Protocol Number: U1111-1261-1912 Start Date*: 2022-07-21
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
    Medical condition: Obesity, Overweight
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Ongoing) DK (Ongoing) FI (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 14:50:51 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA